In our study, neutropenia and CMV infection were more common in the ruxolitinib/steroid group, which could be managed with granulocyte colony-stimulating factor (G-CSF) and antiviral agents (ganciclovir/foscarnet). This evidence concerns the gene CSF3 and neutropenia.